Myasthenia gravis

Last updated: December 12, 2025

Myasthenia gravis

Neuro

Neuro

Ischemic stroke
Transient ischemic attack
Intracerebral hemorrhage
Saccular aneurysm
Subarachnoid hemorrhage
Subdural hematoma
Epidural hematoma
Meningitis
Encephalitis
Brain abscess
Cavernous sinus thrombosis
Epidural abscess
Creutzfeldt-Jakob disease
Seizures and epilepsy
Febrile seizure
Migraine
Tension headache
Cluster headache
Hepatic encephalopathy
Reye syndrome
Wernicke-Korsakoff syndrome
Beriberi
Alzheimer disease
Frontotemporal dementia
Vascular dementia
Dementia with Lewy bodies
Broca aphasia
Wernicke aphasia
Kluver-Bucy syndrome
Multiple sclerosis
Transverse myelitis
Central pontine myelinolysis
Acute disseminated encephalomyelitis
Charcot-Marie-Tooth disease
Guillain-Barre syndrome
Normal pressure hydrocephalus
Chiari malformation
Septo-optic dysplasia
Dandy-Walker malformation
Tethered spinal cord syndrome
Spina bifida
Cerebral palsy
Rett syndrome
Aqueductal stenosis
Syringomyelia
Muscular dystrophy
Neurofibromatosis
von Hippel-Lindau disease
Ataxia-telangiectasia
Tuberous sclerosis
Sturge-Weber syndrome
Bell palsy
Trigeminal neuralgia
Shaken baby syndrome
Concussion and traumatic brain injury
Brain herniation
Idiopathic intracranial hypertension
Cauda equina syndrome
Brown-Sequard Syndrome
Neurogenic bladder
Parkinson disease
Essential tremor
Restless legs syndrome
Neuroleptic malignant syndrome
Vertigo
Meniere disease
Labyrinthitis
Acoustic neuroma (schwannoma)
Amyotrophic lateral sclerosis
Spinal muscular atrophy
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Sciatica
Carpal tunnel syndrome
Winged scapula
Ulnar claw
Erb-Duchenne palsy
Thoracic outlet syndrome
Klumpke paralysis
Orthostatic hypotension
Horner syndrome
Pediatric brain tumors
Adult brain tumors
Eustachian tube dysfunction
Otitis externa
Otitis media
Tympanic membrane perforation
Conductive hearing loss
Cataract
Glaucoma
Corneal ulcer
Retinoblastoma
Diabetic retinopathy
Retinopathy of prematurity
Retinal detachment
Age-related macular degeneration
Keratitis
Orbital cellulitis
Periorbital cellulitis
Eyelid disorders: Clinical sciences
Hordeolum (stye)
Conjunctivitis
Uveitis
Color blindness
Hemianopsia
Homonymous hemianopsia
Cortical blindness
Bitemporal hemianopsia
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
General anesthetics
Local anesthetics
Migraine medications
Nonbenzodiazepine anticonvulsants
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Sympathomimetics: Direct agonists
Major depressive disorder
Premenstrual dysphoric disorder
Major depressive disorder with seasonal pattern
Bipolar and related disorders
Suicide
Agoraphobia
Generalized anxiety disorder
Panic disorder
Social anxiety disorder
Obsessive-compulsive disorder
Body dysmorphic disorder
Body focused repetitive disorders
Post-traumatic stress disorder
Somatic symptom disorder
Physical and sexual abuse
Schizophrenia
Delusional disorder
Schizoaffective disorder
Schizophreniform disorder
Alcohol use disorder
Tobacco use disorder
Opioid use disorder
Cannabis use disorder
Cocaine use disorder
Cluster A personality disorders
Cluster B personality disorders
Cluster C personality disorders
Tourette syndrome
Attention deficit hyperactivity disorder
Autism spectrum disorder
Learning disability
Disruptive, impulse control, and conduct disorders
Anorexia nervosa
Bulimia nervosa
Encopresis
Enuresis
Insomnia
Bruxism
Narcolepsy (NORD)
Nocturnal enuresis
Night terrors
Dissociative disorders
Amnesia
Delirium
Factitious disorder
Serotonin and norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors
Monoamine oxidase inhibitors
Tricyclic antidepressants
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Psychomotor stimulants

Flashcards

Myasthenia gravis

0 of 12 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

Start
A 40-year-old woman begins complaining of dyspnea while recovering in the post-anesthesia care unit. Earlier in the day, the patient underwent a laparoscopic cholecystectomy for treatment of symptomatic gallstones. Past medical history is unremarkable. Her temperature is 37.7°C (99.9°F), pulse is 93/min, respiratory rate is 24/min and blood pressure is 125/72 mmHg. Physical examination shows the patient in distress with shallow breaths, using accessory muscles. In addition, the patient is observed to have drooping of the eyelids and corners of the mouth bilaterally. Pupils are 3 cm bilaterally and reactive to light. An arterial blood gas measurement reveals the following findings:  

 Laboratory Value  Result  Reference Range 
 pH  7.31  7.35-7.45 
 PaCO2  56 mmHg  33-45 mmHg 
 PaO2  71 mmHg  75-105 mmHg 
 Bicarbonate  25 mmol/L  22-28 mmol/L 
   
The patient’s condition improves with administration of edrophonium chloride. Which of the following best describes the cause of this patient’s condition? 

Transcript

Watch video only

Myasthenia gravis comes from the Greek word ‘myasthenia’, meaning muscle weakness; and the Latin word ‘gravis’, meaning severe. So, myasthenia gravis is an autoimmune condition that causes serious muscle weakness.

First, let's focus on physiology and how muscles normally work. Whether you’re reaching for a slice of pizza or sinking that perfect shot in basketball, it all starts in the brain. The upper motor neuron of the cerebral cortex fires an action potential down the spinal cord to activate lower motor neurons. Next, lower motor neurons pick up these signals and pass them along their axons toward terminal branches and axon terminals, all the way to skeletal muscle fibers.

This communication site between the lower motor neuron and the skeletal muscle fiber is known as the neuromuscular junction, which consists of three main parts. First, there’s the presynaptic membrane, which is the axon terminal of the lower motor neuron packed with acetylcholine vesicles. Acetylcholine is actually the neurotransmitter that enables muscle contraction. Next, there’s the postsynaptic membrane, which is the membrane of the skeletal muscle fiber, rich in nicotinic acetylcholine receptors.

Finally, this tiny space between two membranes is called the synaptic cleft and contains the enzyme acetylcholine esterase.

Now, the arrival of the action potential at the axon terminal triggers the opening of voltage-gated calcium channels in the presynaptic membrane, allowing calcium ions to rush in. This triggers the acetylcholine vesicles to fuse with the presynaptic membrane and release acetylcholine into the synaptic cleft. Once inside the cleft, acetylcholine moves across to bind nicotinic acetylcholine receptors on the postsynaptic membrane. Eventually, this binding triggers the muscle cell to depolarize, setting off a chain of intracellular events that lead to contraction. Once the contraction is over, acetylcholine is broken down by acetylcholine esterase, allowing the muscle to relax and prepare for the next signal.

In myasthenia gravis, the immune system produces antibodies that disrupt the normal function of nicotinic acetylcholine receptors. Now, there are three types of autoantibodies. First, we have blocking antibodies, which bind and block acetylcholine receptors, so acetylcholine can’t activate them. Next, there are binding antibodies, which bind the receptors and activate the complement system, eventually destroying them. Finally, the third type includes modulating antibodies, which bind the receptors and trigger the muscle cell to pull the entire receptor inside.

As more receptors are blocked, destroyed, or removed from the postsynaptic membrane, it becomes harder for muscles to receive signals, leading to muscle weakness.

But that's not all. Sometimes, the immune system does not directly attack the acetylcholine receptors. Instead, it targets other important proteins that help neuromuscular junctions work properly, like Muscle Specific Kinase and Lipoprotein Related Protein 4. When they are disrupted, the connection between nerves and muscles becomes unstable or weak, making it even harder for signals to reach the muscle and causing further muscle weakness.

Now, several risk factors contribute to myasthenia gravis, including thymic abnormalities and genetics. In thymic hyperplasia, the thymus enlarges and forms reactive B-cell follicles that produce autoantibodies. Next up is thymoma, which is a tumor that arises from the epithelial cells of the thymus. Both conditions can cause the thymus to misguide the immune system into attacking acetylcholine receptors.

Next up are genetic factors. Certain HLA subtypes, which are genes that help control the immune system, can make someone more likely to develop autoimmune conditions like myasthenia gravis. Moreover, myasthenia gravis often shows up alongside other autoimmune diseases, such as thyroiditis, lupus, or rheumatoid arthritis.

Now, moving to clinical manifestations. As the immune system blocks, destroys or removes receptors from the postsynaptic membrane, muscles have a hard time receiving signals. Ultimately this leads to muscle weakness and fatigue, which is more pronounced in the proximal muscles.

Remember when you were a kid and spent the whole day in the backyard shooting basketballs? Imagine that after a few throws your muscles start to feel weak. You’d have to stop and rest before you could keep playing. Well, that’s what it’s like for someone with myasthenia gravis. Their muscles get tired quickly, even with simple things like brushing their teeth or combing their hair.

Key Takeaways

Myasthenia gravis is an autoimmune disease, specifically a type II hypersensitivity disorder, which is characterized by autoantibodies against nicotinic acetylcholine receptors on the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn't received. Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Symptoms can range from mild to severe and may include drooping eyelids, difficulty speaking or swallowing, and muscle weakness in the arms and legs. Treatment involves immunosuppressive drugs like prednisolone, and acetylcholinesterase inhibitors like neostigmine. The purpose is to reduce the immune system's attack on the muscle and to increase muscle strength.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). " Elsevier Limited (UK) (2022. Page 718-720 )
  2. "Conn's Current Therapy 2025. Available from: ClinicalKey Student" Elsevier Limited (UK) (2024. Page 806-811 )
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition)" Elsevier Limited (UK) (2023. Page 461-471 )